The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | Exploring ILD drugs in lung cancer: research gaps and opportunities
Matthew Hatton, MBChB, MSc, FRCP, FRCR, University of Sheffield, Sheffield, UK, highlights a gap in research regarding the potential benefits of drugs used in interstitial lung disease (ILD) treatment for lung cancer patients. While some drugs like nintedanib show anticancer properties and may reduce respiratory toxicities, systematic trials exploring their efficacy in cancer outcomes are lacking. Prof. Hatton advocates for addressing this need by conducting trials to evaluate whether these treatments can be optimized to minimize toxicity and enhance patient acceptability. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
